JP2017513932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513932A5 JP2017513932A5 JP2017503794A JP2017503794A JP2017513932A5 JP 2017513932 A5 JP2017513932 A5 JP 2017513932A5 JP 2017503794 A JP2017503794 A JP 2017503794A JP 2017503794 A JP2017503794 A JP 2017503794A JP 2017513932 A5 JP2017513932 A5 JP 2017513932A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- triazaspiro
- decan
- fluoro
- oxobutan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 268
- -1 1- (1- (3-fluoro-4-methoxyphenyl) -3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5] decane -8-yl) -3-methyl-1-oxobutan-2-yl Chemical group 0.000 claims description 188
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 65
- 150000001875 compounds Chemical class 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 48
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 229910052760 oxygen Inorganic materials 0.000 claims description 39
- 125000005843 halogen group Chemical group 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 125000005842 heteroatom Chemical group 0.000 claims description 34
- 229920006395 saturated elastomer Polymers 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 239000005711 Benzoic acid Substances 0.000 claims description 10
- 235000010233 benzoic acid Nutrition 0.000 claims description 10
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims description 5
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 206010064190 Cholestatic pruritus Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- DDLPGTOHZZKQLP-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC(C(F)(F)F)=CC=C1F DDLPGTOHZZKQLP-UHFFFAOYSA-N 0.000 claims description 2
- KFTMKTOJVHOBGJ-HSZRJFAPSA-N 2-fluoro-N-[(2R)-3-methyl-1-[3-methyl-1-(2-methylindazol-5-yl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-1-oxobutan-2-yl]-5-(trifluoromethyl)benzamide Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC4=CN(N=C4C=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F KFTMKTOJVHOBGJ-HSZRJFAPSA-N 0.000 claims description 2
- YGDNQVHIOIWKCP-JOCHJYFZSA-N 2-fluoro-N-[(2R)-3-methyl-1-[3-methyl-1-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-1-oxobutan-2-yl]-5-(trifluoromethyl)benzamide Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=CC4=C(N(C(O4)=O)C)C=3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F YGDNQVHIOIWKCP-JOCHJYFZSA-N 0.000 claims description 2
- CALWUCIHXRLQQU-HSZRJFAPSA-N 2-fluoro-N-[(2R)-3-methyl-1-[3-methyl-1-[(2-methyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)methyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-1-oxobutan-2-yl]-5-(trifluoromethyl)benzamide Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=4N(C=C3)N=C(N=4)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F CALWUCIHXRLQQU-HSZRJFAPSA-N 0.000 claims description 2
- ZGWXCVZYJDJXBF-OAQYLSRUSA-N 2-fluoro-N-[(2R)-3-methyl-1-[3-methyl-2,4-dioxo-1-(2-oxo-3H-1,3-benzoxazol-5-yl)-1,3,8-triazaspiro[4.5]decan-8-yl]-1-oxobutan-2-yl]-5-(trifluoromethyl)benzamide Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=CC4=C(NC(O4)=O)C=3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F ZGWXCVZYJDJXBF-OAQYLSRUSA-N 0.000 claims description 2
- OJQHZZIHMKRVBA-UHFFFAOYSA-N 2-fluoro-N-[1-[1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-2-methyl-1-oxopropan-2-yl]-5-(trifluoromethyl)benzamide Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C(C(C)(C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O OJQHZZIHMKRVBA-UHFFFAOYSA-N 0.000 claims description 2
- POTURENPSFEWGN-HSZRJFAPSA-N 3-ethyl-N-[(2R)-3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl]benzamide Chemical compound C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC=1 POTURENPSFEWGN-HSZRJFAPSA-N 0.000 claims description 2
- VJJKTFFNAHQWJT-OAQYLSRUSA-N 4-[8-[(2R)-2-[[2-fluoro-5-(trifluoromethoxy)benzoyl]amino]-3-methylbutanoyl]-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl]benzoic acid Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)OC(F)(F)F VJJKTFFNAHQWJT-OAQYLSRUSA-N 0.000 claims description 2
- FUGRDPNAIONVQE-JOCHJYFZSA-N 4-[8-[(2R)-2-[[2-fluoro-5-(trifluoromethoxy)benzoyl]amino]-3-methylbutanoyl]-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl]benzoic acid Chemical compound CC(C)[C@@H](NC(=O)C1=C(F)C=CC(OC(F)(F)F)=C1)C(=O)N1CCC2(CC1)N(CN(C)C2=O)C1=CC=C(C=C1)C(O)=O FUGRDPNAIONVQE-JOCHJYFZSA-N 0.000 claims description 2
- XTHYGPKTTMYUHE-JOCHJYFZSA-N 4-[8-[(2R)-2-[[3-chloro-5-(trifluoromethyl)benzoyl]amino]-3-methylbutanoyl]-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl]benzoic acid Chemical compound ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=C(C=1)C(F)(F)F XTHYGPKTTMYUHE-JOCHJYFZSA-N 0.000 claims description 2
- LAAYUKAQBBWYLR-RUZDIDTESA-N 5-ethyl-2-fluoro-N-[(2R)-1-[1-[4-(methanesulfonamido)phenyl]-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]-3-methyl-1-oxobutan-2-yl]benzamide Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)NS(=O)(=O)C)C)=O)CC2)C(C)C)C=1)F LAAYUKAQBBWYLR-RUZDIDTESA-N 0.000 claims description 2
- OGGLMNLWYAICPS-VCUSLETLSA-N 5-ethyl-2-fluoro-N-[(2R)-3-methoxy-1-[1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-1-oxobutan-2-yl]benzamide Chemical compound CCC1=CC=C(F)C(=C1)C(=O)N[C@H](C(C)OC)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OC)C=C1 OGGLMNLWYAICPS-VCUSLETLSA-N 0.000 claims description 2
- AISJEVBDBCFJKD-RUZDIDTESA-N 5-ethyl-2-fluoro-N-[(2R)-3-methyl-1-[3-methyl-1-(4-methylsulfonylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]-1-oxobutan-2-yl]benzamide Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)S(=O)(=O)C)C)=O)CC2)C(C)C)C=1)F AISJEVBDBCFJKD-RUZDIDTESA-N 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- GIBOXIQBZGLXHE-HSZRJFAPSA-N BrC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C Chemical compound BrC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C GIBOXIQBZGLXHE-HSZRJFAPSA-N 0.000 claims description 2
- XQWCVMSRUVGIQX-HSZRJFAPSA-N BrC=1C=C(C=CC1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C Chemical compound BrC=1C=C(C=CC1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C XQWCVMSRUVGIQX-HSZRJFAPSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- BVYYDEKYMCUJBZ-XMMPIXPASA-N C(#N)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C(=CC=C2)C)F)=O)=O)=O)C Chemical compound C(#N)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C(=CC=C2)C)F)=O)=O)=O)C BVYYDEKYMCUJBZ-XMMPIXPASA-N 0.000 claims description 2
- JQXPNFVKZCESQZ-RUZDIDTESA-N C(#N)CN1C(N(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)C2=CC=C(C=C2)OC)=O Chemical compound C(#N)CN1C(N(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)C2=CC=C(C=C2)OC)=O JQXPNFVKZCESQZ-RUZDIDTESA-N 0.000 claims description 2
- DSWPYXJSXDRMLQ-RUZDIDTESA-N C(#N)CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)C2=CC=CC=C2 Chemical compound C(#N)CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)C2=CC=CC=C2 DSWPYXJSXDRMLQ-RUZDIDTESA-N 0.000 claims description 2
- PPTLTNOXXJOTPB-UHFFFAOYSA-N C(#N)COC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C(C(C(C)C)C2(C(=O)N)C(C=CC(=C2)CC)F)=O)=O)C Chemical compound C(#N)COC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C(C(C(C)C)C2(C(=O)N)C(C=CC(=C2)CC)F)=O)=O)C PPTLTNOXXJOTPB-UHFFFAOYSA-N 0.000 claims description 2
- AJASGMZXUFJNGO-AREMUKBSSA-N C(C)(=O)NC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)=O)C Chemical compound C(C)(=O)NC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)=O)C AJASGMZXUFJNGO-AREMUKBSSA-N 0.000 claims description 2
- PKLSBRDTQQVDFK-FDDCHVKYSA-N C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)[C@H](C)OC)C=C(C1)F Chemical compound C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)[C@H](C)OC)C=C(C1)F PKLSBRDTQQVDFK-FDDCHVKYSA-N 0.000 claims description 2
- QYGDBEKYTXDNBG-GBXCKJPGSA-N C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C=CC1 Chemical compound C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C=CC1 QYGDBEKYTXDNBG-GBXCKJPGSA-N 0.000 claims description 2
- CAMLYXXGGGUBTP-FDDCHVKYSA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)[C@H](C)OC)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)[C@H](C)OC)C1)F CAMLYXXGGGUBTP-FDDCHVKYSA-N 0.000 claims description 2
- YXAWXHAIPIUYAF-RUZDIDTESA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=CC=4N(C=3)C(=NC=4)C)=O)C)=O)CC2)C(C)C)C=1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=CC=4N(C=3)C(=NC=4)C)=O)C)=O)CC2)C(C)C)C=1)F YXAWXHAIPIUYAF-RUZDIDTESA-N 0.000 claims description 2
- RDEALTAUSNJWHE-XMMPIXPASA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C1)F RDEALTAUSNJWHE-XMMPIXPASA-N 0.000 claims description 2
- PYZWTJUUYLSWCJ-AREMUKBSSA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(OCC(=O)O)C=C3)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(OCC(=O)O)C=C3)C)=O)CC2)C(C)C)C1)F PYZWTJUUYLSWCJ-AREMUKBSSA-N 0.000 claims description 2
- GOECOLXTEALSPU-YADARESESA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C1)F GOECOLXTEALSPU-YADARESESA-N 0.000 claims description 2
- CSUDRQYUGZFSQX-XMMPIXPASA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C1)F CSUDRQYUGZFSQX-XMMPIXPASA-N 0.000 claims description 2
- KIYAHTYTVMZFTM-UQBPGWFLSA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C1)F KIYAHTYTVMZFTM-UQBPGWFLSA-N 0.000 claims description 2
- KIYAHTYTVMZFTM-KBMIEXCESA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C1)F KIYAHTYTVMZFTM-KBMIEXCESA-N 0.000 claims description 2
- WNZZCFYRMROUMP-HSZRJFAPSA-N C(N)(=O)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C(=CC=C2)C)F)=O)=O)=O)C Chemical compound C(N)(=O)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C(=CC=C2)C)F)=O)=O)=O)C WNZZCFYRMROUMP-HSZRJFAPSA-N 0.000 claims description 2
- DTQQOOVTIDJDJA-HSZRJFAPSA-N C(N)(=O)C=1C=C(C=CC=1)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C(=CC=C1)C)F)=O)=O)=O)C Chemical compound C(N)(=O)C=1C=C(C=CC=1)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C(=CC=C1)C)F)=O)=O)=O)C DTQQOOVTIDJDJA-HSZRJFAPSA-N 0.000 claims description 2
- UBCHOWVYKLDUSP-RUZDIDTESA-N C1(CC1)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=CC1 Chemical compound C1(CC1)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=CC1 UBCHOWVYKLDUSP-RUZDIDTESA-N 0.000 claims description 2
- LMBIYMSSVZDHLJ-XMMPIXPASA-N C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C1)F Chemical compound C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C1)F LMBIYMSSVZDHLJ-XMMPIXPASA-N 0.000 claims description 2
- CVJCFLXYSPTJMF-RUZDIDTESA-N C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)C(C)C)C=1)F Chemical compound C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)C(C)C)C=1)F CVJCFLXYSPTJMF-RUZDIDTESA-N 0.000 claims description 2
- MJWGGVKFEQYJPH-UHFFFAOYSA-N CC(C)C(C(N(CC1)CCC1(C(N(C)C1)=O)N1C1=C(B(O)O)C=CC=C1)=O)NC(C(C=CC=C1C)=C1F)=O Chemical compound CC(C)C(C(N(CC1)CCC1(C(N(C)C1)=O)N1C1=C(B(O)O)C=CC=C1)=O)NC(C(C=CC=C1C)=C1F)=O MJWGGVKFEQYJPH-UHFFFAOYSA-N 0.000 claims description 2
- TWKSGEPTRAKZPK-UHFFFAOYSA-N CC(C)C(NC(=O)c1ccccn1)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)c1ccc2[nH]ncc2c1 Chemical compound CC(C)C(NC(=O)c1ccccn1)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)c1ccc2[nH]ncc2c1 TWKSGEPTRAKZPK-UHFFFAOYSA-N 0.000 claims description 2
- YEFSFRPUBODATL-VWFFAVBPSA-N CC(C)[C@@H](NC(=O)C12CC3CC(CC(C3)C1)C2)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C2NN=CC2=C1 Chemical compound CC(C)[C@@H](NC(=O)C12CC3CC(CC(C3)C1)C2)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C2NN=CC2=C1 YEFSFRPUBODATL-VWFFAVBPSA-N 0.000 claims description 2
- AQAUWVJPVMGTSC-XMMPIXPASA-N CC(C)[C@@H](NC(=O)C1=C(F)C(C)=CC=C1)C(=O)N1CCC2(CC1)N(CN(C)C2=O)C1=CC(=CC=C1)C#N Chemical compound CC(C)[C@@H](NC(=O)C1=C(F)C(C)=CC=C1)C(=O)N1CCC2(CC1)N(CN(C)C2=O)C1=CC(=CC=C1)C#N AQAUWVJPVMGTSC-XMMPIXPASA-N 0.000 claims description 2
- OEARUEAHUJSOKP-XMMPIXPASA-N CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(NC2COC2)C=C1 Chemical compound CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(NC2COC2)C=C1 OEARUEAHUJSOKP-XMMPIXPASA-N 0.000 claims description 2
- BYITUQUWMVRENA-OAQYLSRUSA-N CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OC(F)(F)F)C=C1 Chemical compound CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OC(F)(F)F)C=C1 BYITUQUWMVRENA-OAQYLSRUSA-N 0.000 claims description 2
- HOZZPCLPYSGHNM-JOCHJYFZSA-N CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(CN(C)C2=O)C1=CC=C(C=C1)C(O)=O Chemical compound CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(CN(C)C2=O)C1=CC=C(C=C1)C(O)=O HOZZPCLPYSGHNM-JOCHJYFZSA-N 0.000 claims description 2
- XNSIWDJGVGEHNG-KRZHYRLCSA-N CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OC([2H])([2H])[2H])=O)C)=O)CC1)NC(C1=CC(=CC(=C1)F)C(F)(F)F)=O)C Chemical compound CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OC([2H])([2H])[2H])=O)C)=O)CC1)NC(C1=CC(=CC(=C1)F)C(F)(F)F)=O)C XNSIWDJGVGEHNG-KRZHYRLCSA-N 0.000 claims description 2
- OODKHHDCOOFVEO-JOCHJYFZSA-N CC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=CN=1 Chemical compound CC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=CN=1 OODKHHDCOOFVEO-JOCHJYFZSA-N 0.000 claims description 2
- LEQNBKIUGXBMTP-RUZDIDTESA-N CC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C2CCOCC2)C=CC=1 Chemical compound CC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C2CCOCC2)C=CC=1 LEQNBKIUGXBMTP-RUZDIDTESA-N 0.000 claims description 2
- NYLKTDGFIYPAJX-JOCHJYFZSA-N CC=1C=C(C(=O)N[C@@H](C(N2CCC3(COC(N3C3=CC=CC=C3)=O)CC2)=O)C(C)C)C=CC1 Chemical compound CC=1C=C(C(=O)N[C@@H](C(N2CCC3(COC(N3C3=CC=CC=C3)=O)CC2)=O)C(C)C)C=CC1 NYLKTDGFIYPAJX-JOCHJYFZSA-N 0.000 claims description 2
- LEQNBKIUGXBMTP-VWLOTQADSA-N CC=1C=C(C(=O)N[C@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C2CCOCC2)C=CC1 Chemical compound CC=1C=C(C(=O)N[C@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C2CCOCC2)C=CC1 LEQNBKIUGXBMTP-VWLOTQADSA-N 0.000 claims description 2
- NGJPRALBUUSWHM-RUZDIDTESA-N CCC1=CC=C(F)C(=C1)C(=O)N[C@H](C(C)C)C(=O)N1CCC2(CC1)N(CN(CC(O)=O)C2=O)C1=CC=CC=C1 Chemical compound CCC1=CC=C(F)C(=C1)C(=O)N[C@H](C(C)C)C(=O)N1CCC2(CC1)N(CN(CC(O)=O)C2=O)C1=CC=CC=C1 NGJPRALBUUSWHM-RUZDIDTESA-N 0.000 claims description 2
- LLBPNKXHARGZSU-XMMPIXPASA-N CCC1=CC=CC(=C1)C(=O)N[C@H](C(C)C)C(=O)N1CCC2(CC1)N(CN(C)C2=O)C1=CC=CC=C1 Chemical compound CCC1=CC=CC(=C1)C(=O)N[C@H](C(C)C)C(=O)N1CCC2(CC1)N(CN(C)C2=O)C1=CC=CC=C1 LLBPNKXHARGZSU-XMMPIXPASA-N 0.000 claims description 2
- HIDNZZJXDDHNIT-HSZRJFAPSA-N CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)C)=O)=O)C2=CC=C(C(=O)O)C=C2 Chemical compound CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)C)=O)=O)C2=CC=C(C(=O)O)C=C2 HIDNZZJXDDHNIT-HSZRJFAPSA-N 0.000 claims description 2
- DGQSCTYDBGYFLL-XMMPIXPASA-N CN1CN(C2=CC=C(C=C2)C(O)=O)C2(CCN(CC2)C(=O)[C@H](NC(=O)C2=C(F)C=CC(=C2)C(F)(F)F)C2CCCC2)C1=O Chemical compound CN1CN(C2=CC=C(C=C2)C(O)=O)C2(CCN(CC2)C(=O)[C@H](NC(=O)C2=C(F)C=CC(=C2)C(F)(F)F)C2CCCC2)C1=O DGQSCTYDBGYFLL-XMMPIXPASA-N 0.000 claims description 2
- CQXUXMITFAPFPB-IXXGTQFESA-N COC(C)[C@@H](NC(=O)C1=CC(=CC=C1F)C1CC1)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OC)C=C1 Chemical compound COC(C)[C@@H](NC(=O)C1=CC(=CC=C1F)C1CC1)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OC)C=C1 CQXUXMITFAPFPB-IXXGTQFESA-N 0.000 claims description 2
- QQXOMARFNQGCBI-HSZRJFAPSA-N COC1=CC=C(CN2C(=O)N(C)C(=O)C22CCN(CC2)C(=O)[C@H](NC(=O)C2=C(F)C=CC(=C2)C(F)(F)F)C(C)C)C=C1 Chemical compound COC1=CC=C(CN2C(=O)N(C)C(=O)C22CCN(CC2)C(=O)[C@H](NC(=O)C2=C(F)C=CC(=C2)C(F)(F)F)C(C)C)C=C1 QQXOMARFNQGCBI-HSZRJFAPSA-N 0.000 claims description 2
- YIKQJSUNKOCSEN-XMMPIXPASA-N COC=1C=C(C=CC1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C Chemical compound COC=1C=C(C=CC1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C YIKQJSUNKOCSEN-XMMPIXPASA-N 0.000 claims description 2
- BMPQFGJILDCURA-NZQKXSOJSA-N CO[C@H]([C@H](C(=O)N1CCC2(C(N(CN2C2=CC=CC=C2)C)=O)CC1)NC(C1=CC(=CC=C1)C)=O)C Chemical compound CO[C@H]([C@H](C(=O)N1CCC2(C(N(CN2C2=CC=CC=C2)C)=O)CC1)NC(C1=CC(=CC=C1)C)=O)C BMPQFGJILDCURA-NZQKXSOJSA-N 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- USNCHQHJAPTDNK-XVPAFAEQSA-N ClC1(CC=CC=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C Chemical compound ClC1(CC=CC=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C USNCHQHJAPTDNK-XVPAFAEQSA-N 0.000 claims description 2
- CEGYCUYQYZXRGH-HSZRJFAPSA-N ClC1=C(C=CC=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C Chemical compound ClC1=C(C=CC=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C CEGYCUYQYZXRGH-HSZRJFAPSA-N 0.000 claims description 2
- FLHHNKLGKZDSCR-JOCHJYFZSA-N ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C=C(C=1)C(F)(F)F Chemical compound ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C=C(C=1)C(F)(F)F FLHHNKLGKZDSCR-JOCHJYFZSA-N 0.000 claims description 2
- LEQGWCFLSAHFNZ-HSZRJFAPSA-N ClC=1C=C(C=CC1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C Chemical compound ClC=1C=C(C=CC1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC=C2)C)=O)=O)=O)C LEQGWCFLSAHFNZ-HSZRJFAPSA-N 0.000 claims description 2
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 108010037464 Cyclooxygenase 1 Proteins 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 claims description 2
- FRPWXZRVHMHXCN-OAQYLSRUSA-N FC(OC=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C1)F)F Chemical compound FC(OC=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C1)F)F FRPWXZRVHMHXCN-OAQYLSRUSA-N 0.000 claims description 2
- DPEYSCNSVHLKSC-JOCHJYFZSA-N FC(OC=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=1)F)F Chemical compound FC(OC=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=1)F)F DPEYSCNSVHLKSC-JOCHJYFZSA-N 0.000 claims description 2
- PDFLRDQOOPRETN-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC(=CC=C3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC(=CC=C3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F PDFLRDQOOPRETN-JOCHJYFZSA-N 0.000 claims description 2
- FNQOHPHAPZGYHQ-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC4=C(NC(O4)=O)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC4=C(NC(O4)=O)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F FNQOHPHAPZGYHQ-OAQYLSRUSA-N 0.000 claims description 2
- CWSQVYFGLYCBFT-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F CWSQVYFGLYCBFT-OAQYLSRUSA-N 0.000 claims description 2
- HUVDKCPZKDJIRU-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)F)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)F)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F HUVDKCPZKDJIRU-OAQYLSRUSA-N 0.000 claims description 2
- WHVKKPNNIROQJR-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F WHVKKPNNIROQJR-JOCHJYFZSA-N 0.000 claims description 2
- GQXJQATUXRXHHZ-VCUSLETLSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F GQXJQATUXRXHHZ-VCUSLETLSA-N 0.000 claims description 2
- NZYFOHBJKUCFLW-RUZDIDTESA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OCC3COC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OCC3COC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F NZYFOHBJKUCFLW-RUZDIDTESA-N 0.000 claims description 2
- MLOHOBZHEYWWGC-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OCCO)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OCCO)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F MLOHOBZHEYWWGC-HSZRJFAPSA-N 0.000 claims description 2
- TXPSXZIHPCEXFF-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F TXPSXZIHPCEXFF-OAQYLSRUSA-N 0.000 claims description 2
- OMGUNRUFPYKNOG-WZONZLPQSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)[C@@H](CC)C)C=CC=C1C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)[C@@H](CC)C)C=CC=C1C OMGUNRUFPYKNOG-WZONZLPQSA-N 0.000 claims description 2
- FNWFYYUCVVMUMO-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=NC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=NC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F FNWFYYUCVVMUMO-HXUWFJFHSA-N 0.000 claims description 2
- WVJFJUVNPHYXQD-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=[N+](C=C3)[O-])=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=[N+](C=C3)[O-])=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F WVJFJUVNPHYXQD-HXUWFJFHSA-N 0.000 claims description 2
- QARWOGZYCQXGSQ-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CN(C(C=C3)=O)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CN(C(C=C3)=O)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F QARWOGZYCQXGSQ-OAQYLSRUSA-N 0.000 claims description 2
- JFJLUMPWZCAMGQ-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=NC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=NC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F JFJLUMPWZCAMGQ-HXUWFJFHSA-N 0.000 claims description 2
- WBYXLXUXBRZQMG-LJQANCHMSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=NN(C=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=NN(C=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F WBYXLXUXBRZQMG-LJQANCHMSA-N 0.000 claims description 2
- SVIMIKSMBLUDTA-OBFZPWGMSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3CCC(CC3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3CCC(CC3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F SVIMIKSMBLUDTA-OBFZPWGMSA-N 0.000 claims description 2
- FXWGYDPLALEKQP-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3CCOCC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3CCOCC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F FXWGYDPLALEKQP-HXUWFJFHSA-N 0.000 claims description 2
- WNXSJVVSLRKTOJ-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=C4C(=NC3)NC=C4)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=C4C(=NC3)NC=C4)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F WNXSJVVSLRKTOJ-OAQYLSRUSA-N 0.000 claims description 2
- CJYDPDOXVLTDPZ-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=C4C=NN(C4=CC3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=C4C=NN(C4=CC3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F CJYDPDOXVLTDPZ-HSZRJFAPSA-N 0.000 claims description 2
- ICGDCTCMAMLBLT-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NC=CC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NC=CC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F ICGDCTCMAMLBLT-HXUWFJFHSA-N 0.000 claims description 2
- HNOOHVKPFGVHJU-LJQANCHMSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NN(C=3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NN(C=3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F HNOOHVKPFGVHJU-LJQANCHMSA-N 0.000 claims description 2
- BHOCDSKRDCALBO-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC(=NC=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC(=NC=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F BHOCDSKRDCALBO-JOCHJYFZSA-N 0.000 claims description 2
- MWGXXSBLEBXYHN-XMMPIXPASA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC4=C(N=C(O4)C)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC4=C(N=C(O4)C)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F MWGXXSBLEBXYHN-XMMPIXPASA-N 0.000 claims description 2
- NAYGITXNXIHYHT-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=4N(C=C3)C=CN=4)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=4N(C=C3)C=CN=4)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F NAYGITXNXIHYHT-HSZRJFAPSA-N 0.000 claims description 2
- KVHCMWYGUSHGEA-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=C(C=C3)F)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=C(C=C3)F)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F KVHCMWYGUSHGEA-JOCHJYFZSA-N 0.000 claims description 2
- NSNMFIWOXTXBIJ-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CN(C(C=C3)=O)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CN(C(C=C3)=O)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F NSNMFIWOXTXBIJ-JOCHJYFZSA-N 0.000 claims description 2
- SHWWECTZMNCFLG-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=NC=CC=N3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=NC=CC=N3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F SHWWECTZMNCFLG-HXUWFJFHSA-N 0.000 claims description 2
- OFTYQIXWGCTZEP-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3CCOCC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3CCOCC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F OFTYQIXWGCTZEP-OAQYLSRUSA-N 0.000 claims description 2
- QMXYZPVXWVDPON-XMMPIXPASA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=C4N=CC=NC4=CC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=C4N=CC=NC4=CC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F QMXYZPVXWVDPON-XMMPIXPASA-N 0.000 claims description 2
- AKJHYCVZXKCNER-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=CC4=C(N(C(O4)=O)C)C=3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=CC4=C(N(C(O4)=O)C)C=3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F AKJHYCVZXKCNER-HSZRJFAPSA-N 0.000 claims description 2
- NIPMGVAATRVWNE-XMMPIXPASA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=CC4=C(N=C(O4)C)C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=CC4=C(N=C(O4)C)C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F NIPMGVAATRVWNE-XMMPIXPASA-N 0.000 claims description 2
- KZRYBDLUQZFKGT-XMMPIXPASA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=CC4=C(NC(=N4)C)C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=CC4=C(NC(=N4)C)C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F KZRYBDLUQZFKGT-XMMPIXPASA-N 0.000 claims description 2
- ZRWJXKPVRKZSMD-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=NN(C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=NN(C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F ZRWJXKPVRKZSMD-HXUWFJFHSA-N 0.000 claims description 2
- JNXAQUUKDDPRNR-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3SC=C(N3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3SC=C(N3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F JNXAQUUKDDPRNR-HXUWFJFHSA-N 0.000 claims description 2
- HSGKPYRCMTXDPI-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CCC(C)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CCC(C)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F HSGKPYRCMTXDPI-HXUWFJFHSA-N 0.000 claims description 2
- UGGCRELAIDTUIN-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC(=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC(=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F UGGCRELAIDTUIN-HSZRJFAPSA-N 0.000 claims description 2
- SYMAHTMNWKYCSK-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC(=C(C(=O)O)C=C3)OC)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC(=C(C(=O)O)C=C3)OC)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F SYMAHTMNWKYCSK-HSZRJFAPSA-N 0.000 claims description 2
- GMXMCKXBUPLWRK-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=C(C=C1)OC Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=C(C=C1)OC GMXMCKXBUPLWRK-HSZRJFAPSA-N 0.000 claims description 2
- LLXKRJNAHLSYTL-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=CC=C1C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=CC=C1C LLXKRJNAHLSYTL-HSZRJFAPSA-N 0.000 claims description 2
- QJCCUDVULRJUPE-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)B(O)O)C)=O)CC2)C(C)C)C=CC=C1C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)B(O)O)C)=O)CC2)C(C)C)C=CC=C1C QJCCUDVULRJUPE-HSZRJFAPSA-N 0.000 claims description 2
- UIAGFPZXZVFJAN-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)S(=O)(=O)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)S(=O)(=O)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F UIAGFPZXZVFJAN-HSZRJFAPSA-N 0.000 claims description 2
- DVRMLOUJYVMVII-AREMUKBSSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)CCCS(=O)(=O)C)=O)CC2)C(C)C)C=CC=C1C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)CCCS(=O)(=O)C)=O)CC2)C(C)C)C=CC=C1C DVRMLOUJYVMVII-AREMUKBSSA-N 0.000 claims description 2
- CVJFHJQGKBIOJF-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F CVJFHJQGKBIOJF-JOCHJYFZSA-N 0.000 claims description 2
- IWULRNJVGTUITM-GAJHUEQPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F IWULRNJVGTUITM-GAJHUEQPSA-N 0.000 claims description 2
- IWULRNJVGTUITM-UZUQRXQVSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F IWULRNJVGTUITM-UZUQRXQVSA-N 0.000 claims description 2
- ITVVCWQFQQWQCY-NTKDMRAZSA-N FC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)[C@@H](CC)C)C=C(C=1)C Chemical compound FC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)[C@@H](CC)C)C=C(C=1)C ITVVCWQFQQWQCY-NTKDMRAZSA-N 0.000 claims description 2
- QBMVYVJWNKXVLA-OAQYLSRUSA-N FC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC1 Chemical compound FC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC1 QBMVYVJWNKXVLA-OAQYLSRUSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 206010072877 Intestinal fibrosis Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 claims description 2
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- WFHYLAWROUXHOF-RUZDIDTESA-N N-[(1R)-1-cyclohexyl-2-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxoethyl]-3-methylbenzamide Chemical compound C1(CCCCC1)[C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=CC=C2)=O)C)=O)CC1)NC(C1=CC(=CC=C1)C)=O WFHYLAWROUXHOF-RUZDIDTESA-N 0.000 claims description 2
- WOACRZWRSBSQRC-JOCHJYFZSA-N N-[(2R)-1-[1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-3-methyl-1-oxobutan-2-yl]benzamide Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=CC=CC=C1)=O)=O)=O)C)=O WOACRZWRSBSQRC-JOCHJYFZSA-N 0.000 claims description 2
- MAAXIYXUGJBYKT-JOCHJYFZSA-N N-[(2R)-1-[1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-3-methyl-1-oxobutan-2-yl]cyclohexanecarboxamide Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(=O)C1CCCCC1)=O)=O)C)=O MAAXIYXUGJBYKT-JOCHJYFZSA-N 0.000 claims description 2
- FMWAZPTZCCGSEF-RUZDIDTESA-N N-[(2R)-1-[1-(3H-benzimidazol-5-yl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]-3-methyl-1-oxobutan-2-yl]-5-ethyl-2-fluorobenzamide Chemical compound N1C=NC2=C1C=C(C=C2)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O)=O)C FMWAZPTZCCGSEF-RUZDIDTESA-N 0.000 claims description 2
- LREGJECKQRKIRO-HSZRJFAPSA-N N-[(2R)-1-[1-(4-ethoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-3-methyl-1-oxobutan-2-yl]-3-fluoro-5-(trifluoromethyl)benzamide Chemical compound CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OCC)=O)C)=O)CC1)NC(C1=CC(=CC(=C1)F)C(F)(F)F)=O)C LREGJECKQRKIRO-HSZRJFAPSA-N 0.000 claims description 2
- NQALDIAARUAZJR-XMMPIXPASA-N N-[(2R)-1-[1-(4-methoxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]-3-methyl-1-oxobutan-2-yl]-3-methylbenzamide Chemical compound COC1=CC=C(C=C1)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=CC(=CC=C1)C)=O)=O)=O)C NQALDIAARUAZJR-XMMPIXPASA-N 0.000 claims description 2
- OGEVRNIAJCFHBG-AREMUKBSSA-N N-[(2R)-1-[1-[4-(2-amino-2-oxoethoxy)phenyl]-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]-3-methyl-1-oxobutan-2-yl]-5-ethyl-2-fluorobenzamide Chemical compound NC(COC1=CC=C(C=C1)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O)=O)C)=O OGEVRNIAJCFHBG-AREMUKBSSA-N 0.000 claims description 2
- LDYHTGGCGXBGDE-UHFFFAOYSA-N N-[3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NC(C(=O)N1CCC2(C(N(C(N2C2=CC=CC=C2)=O)C)=O)CC1)C(C)C LDYHTGGCGXBGDE-UHFFFAOYSA-N 0.000 claims description 2
- RTUNYIMDFLSMRE-UHFFFAOYSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C(CNC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C(CNC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O RTUNYIMDFLSMRE-UHFFFAOYSA-N 0.000 claims description 2
- XBHMMZIIOXYSIV-GOSISDBHSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(=O)C=1SC=CN=1)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(=O)C=1SC=CN=1)=O)=O)C)=O XBHMMZIIOXYSIV-GOSISDBHSA-N 0.000 claims description 2
- DEJMCQZHWIOHMD-LJQANCHMSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C(C)(C)C)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C(C)(C)C)=O)=O)=O)C)=O DEJMCQZHWIOHMD-LJQANCHMSA-N 0.000 claims description 2
- BDMKXRAWQIQRRY-HSZRJFAPSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C)F)=O)=O)=O)C)=O BDMKXRAWQIQRRY-HSZRJFAPSA-N 0.000 claims description 2
- KDWUXZDBISLXEX-RUZDIDTESA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C1CC1)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C1CC1)F)=O)=O)=O)C)=O KDWUXZDBISLXEX-RUZDIDTESA-N 0.000 claims description 2
- ZLEVKVIRYIXIFA-XMMPIXPASA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O)=O)C)=O ZLEVKVIRYIXIFA-XMMPIXPASA-N 0.000 claims description 2
- NEIODLHGDTVZSQ-JOCHJYFZSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)Cl)Cl)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)Cl)Cl)=O)=O)=O)C)=O NEIODLHGDTVZSQ-JOCHJYFZSA-N 0.000 claims description 2
- PHRMWNSITVSNDO-JOCHJYFZSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)F)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)F)F)=O)=O)=O)C)=O PHRMWNSITVSNDO-JOCHJYFZSA-N 0.000 claims description 2
- JNHPOOCMLKCZBW-JOCHJYFZSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)OC(F)F)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)OC(F)F)F)=O)=O)=O)C)=O JNHPOOCMLKCZBW-JOCHJYFZSA-N 0.000 claims description 2
- OGQAHJHTXZWVBP-HSZRJFAPSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)OC)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)OC)F)=O)=O)=O)C)=O OGQAHJHTXZWVBP-HSZRJFAPSA-N 0.000 claims description 2
- XYJHKVSHKNGDFO-OAQYLSRUSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=CC=NC=C1)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=CC=NC=C1)=O)=O)=O)C)=O XYJHKVSHKNGDFO-OAQYLSRUSA-N 0.000 claims description 2
- IKOCHMWIWKLSSW-OAQYLSRUSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=CN=CC=C1)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=CN=CC=C1)=O)=O)=O)C)=O IKOCHMWIWKLSSW-OAQYLSRUSA-N 0.000 claims description 2
- CDSKRHGFXHZEQL-QFIPXVFZSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O CDSKRHGFXHZEQL-QFIPXVFZSA-N 0.000 claims description 2
- CDSKRHGFXHZEQL-JOCHJYFZSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O CDSKRHGFXHZEQL-JOCHJYFZSA-N 0.000 claims description 2
- USPZQBGGBVVQBD-RUZDIDTESA-N N1N=CC2=CC(=CC=C12)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O)=O)C Chemical compound N1N=CC2=CC(=CC=C12)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O)=O)C USPZQBGGBVVQBD-RUZDIDTESA-N 0.000 claims description 2
- ONTHXIMRAUBPSG-OAQYLSRUSA-N N=1NN=NC=1C1=CC=C(C=C1)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)OC(F)F)F)=O)=O)=O)C)=O Chemical compound N=1NN=NC=1C1=CC=C(C=C1)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)OC(F)F)F)=O)=O)=O)C)=O ONTHXIMRAUBPSG-OAQYLSRUSA-N 0.000 claims description 2
- NINPXZCUJKZPPO-VQIWEWKSSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(CN(CCN(C)C)C2=O)C1=CC=C(C=C1)C(O)=O Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(CN(CCN(C)C)C2=O)C1=CC=C(C=C1)C(O)=O NINPXZCUJKZPPO-VQIWEWKSSA-N 0.000 claims description 2
- JRVBKZVVCIANHI-GJFSDDNBSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(CCN(C)C)C2=O)c1ccc(cc1)C(O)=O Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(CCN(C)C)C2=O)c1ccc(cc1)C(O)=O JRVBKZVVCIANHI-GJFSDDNBSA-N 0.000 claims description 2
- LKNXEALWFBTCAW-VQIWEWKSSA-N OC(=O)C(F)(F)F.CN1CN(C2=CC=CC=C2)C2(CCN(CC2)C(=O)[C@H](NC(=O)C2=CC=CC(C)=N2)C2CCCCC2)C1=O Chemical compound OC(=O)C(F)(F)F.CN1CN(C2=CC=CC=C2)C2(CCN(CC2)C(=O)[C@H](NC(=O)C2=CC=CC(C)=N2)C2CCCCC2)C1=O LKNXEALWFBTCAW-VQIWEWKSSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 2
- 229940122144 Prostaglandin receptor antagonist Drugs 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 229940124639 Selective inhibitor Drugs 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 108010016133 acylglycerol kinase Proteins 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000002559 chemokine receptor antagonist Substances 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- UBKHHFOBCZFFKL-UHFFFAOYSA-N cyclopenta[c]pyran Chemical compound C1=COC=C2C=CC=C21 UBKHHFOBCZFFKL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- WNGSYXVSSXGSPQ-HSZRJFAPSA-N methyl N-[4-[8-[(2R)-2-[[2-fluoro-5-(trifluoromethyl)benzoyl]amino]-3-methylbutanoyl]-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl]phenyl]carbamate Chemical compound COC(NC1=CC=C(C=C1)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O WNGSYXVSSXGSPQ-HSZRJFAPSA-N 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000002089 prostaglandin antagonist Substances 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 2
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 claims 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- PJTDHGUEFPHGGZ-JOCHJYFZSA-N methyl 4-[8-[(2R)-2-[[2-fluoro-5-(trifluoromethyl)benzoyl]amino]-3-methylbutanoyl]-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl]benzoate Chemical compound COC(C1=CC=C(C=C1)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O)=O PJTDHGUEFPHGGZ-JOCHJYFZSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 0 *C(*)(C(N(C*C*C(*N(C(C1)=O)N)=C)C1=N)=O)NC(*)=O Chemical compound *C(*)(C(N(C*C*C(*N(C(C1)=O)N)=C)C1=N)=O)NC(*)=O 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- ISVCOTZIKKNJSU-JOCHJYFZSA-N COC(NC1=CC=C(C=C1)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O)=O Chemical compound COC(NC1=CC=C(C=C1)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O)=O ISVCOTZIKKNJSU-JOCHJYFZSA-N 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 229940121927 Phospholipase A1 inhibitor Drugs 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461975123P | 2014-04-04 | 2014-04-04 | |
| US61/975,123 | 2014-04-04 | ||
| PCT/US2015/024338 WO2015154023A1 (en) | 2014-04-04 | 2015-04-03 | Substituted spirocydic inhibitors of autotaxin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019203023A Division JP2020040960A (ja) | 2014-04-04 | 2019-11-08 | オートタキシンの置換スピロ環式阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513932A JP2017513932A (ja) | 2017-06-01 |
| JP2017513932A5 true JP2017513932A5 (enExample) | 2018-05-17 |
| JP6616821B2 JP6616821B2 (ja) | 2019-12-04 |
Family
ID=54241341
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503794A Expired - Fee Related JP6616821B2 (ja) | 2014-04-04 | 2015-04-03 | オートタキシンの置換スピロ環式阻害剤 |
| JP2019203023A Pending JP2020040960A (ja) | 2014-04-04 | 2019-11-08 | オートタキシンの置換スピロ環式阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019203023A Pending JP2020040960A (ja) | 2014-04-04 | 2019-11-08 | オートタキシンの置換スピロ環式阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10011601B2 (enExample) |
| EP (1) | EP3125895A4 (enExample) |
| JP (2) | JP6616821B2 (enExample) |
| KR (1) | KR20160133004A (enExample) |
| CN (1) | CN107106559A (enExample) |
| AP (1) | AP2016009496A0 (enExample) |
| AU (2) | AU2015240519B2 (enExample) |
| CA (1) | CA2943874A1 (enExample) |
| CL (1) | CL2016002516A1 (enExample) |
| CR (1) | CR20160496A (enExample) |
| CU (1) | CU24442B1 (enExample) |
| DO (1) | DOP2016000270A (enExample) |
| EA (1) | EA201691840A1 (enExample) |
| EC (1) | ECSP16084293A (enExample) |
| IL (1) | IL248050A0 (enExample) |
| MD (1) | MD20160116A2 (enExample) |
| MX (1) | MX2016013049A (enExample) |
| PE (1) | PE20170206A1 (enExample) |
| PH (1) | PH12016501922A1 (enExample) |
| SG (1) | SG11201607920RA (enExample) |
| WO (1) | WO2015154023A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| MX368615B (es) | 2012-09-25 | 2019-10-09 | Hoffmann La Roche | Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos. |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| DK3074400T3 (en) | 2013-11-26 | 2018-01-15 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| CU24442B1 (es) | 2014-04-04 | 2019-09-04 | X Rx Inc | Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| JP6876685B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| BR112017026682A2 (pt) | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| AU2016328436B2 (en) | 2015-09-24 | 2020-05-14 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CN108456208B (zh) * | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
| KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
| MX2020007318A (es) * | 2017-09-29 | 2020-08-24 | Takeda Pharmaceuticals Co | Compuesto heterociclico. |
| WO2020051230A1 (en) * | 2018-09-04 | 2020-03-12 | X-Rx, Inc. | Amorphous pharmaceutical compositions and uses thereof |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| JP7545570B2 (ja) * | 2020-08-14 | 2024-09-04 | ノバルティス アーゲー | ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用 |
| TWI904281B (zh) | 2020-11-13 | 2025-11-11 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
| CN112675308B (zh) * | 2020-12-09 | 2023-05-05 | 中国人民解放军军事科学院军事医学研究院 | 抑制enpp2基因和/或蛋白表达的物质在制备治疗多发性骨髓瘤的药物中的应用 |
| JP2024502337A (ja) | 2021-01-05 | 2024-01-18 | ザイダス ライフサイエンシズ リミティド | オートタキシンの新規阻害剤 |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
| WO2024073658A1 (en) * | 2022-09-30 | 2024-04-04 | Genentech, Inc. | Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| TR199902752T2 (xx) | 1997-05-08 | 2000-06-21 | Smithkline Beecham Corporation | Proteaz inhibit�rleri. |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| CA2438272A1 (en) * | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| EP1370211A4 (en) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
| HRP20040311A2 (en) * | 2001-10-01 | 2005-02-28 | Bristol-Myers Squibb Company Cerep SA | Spiro-hydantoin compounds useful as anti-inflammatory agents |
| US20040192674A1 (en) | 2003-02-14 | 2004-09-30 | Marquis Robert W. | Cathepsin L inhibitors |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| WO2005122379A2 (en) * | 2004-05-27 | 2005-12-22 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
| JPWO2006137465A1 (ja) | 2005-06-24 | 2009-01-22 | 塩野義製薬株式会社 | 含窒素複素環誘導体 |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8906859B2 (en) * | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
| CN101534824A (zh) | 2006-11-17 | 2009-09-16 | 艾博特公司 | 作为化学活素受体拮抗剂的氨基吡咯烷 |
| US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
| RU2010142937A (ru) | 2008-03-20 | 2012-04-27 | Форест Лабораториес Холдингс Лимитед (Bm) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ |
| WO2009151644A2 (en) | 2008-06-13 | 2009-12-17 | Yale University | Small molecule inhibitors of autotaxin methods of use |
| WO2010037081A1 (en) | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
| CN102216299B (zh) | 2008-12-01 | 2015-02-11 | 默克专利有限公司 | 作为自体毒素抑制剂的2,5-二氨基取代的吡啶并[4,3-d]嘧啶化合物 |
| EA201101399A1 (ru) | 2009-04-02 | 2012-08-30 | Мерк Патент Гмбх | Гетероциклические соединения в качестве ингибиторов аутотаксина |
| CN102369186B (zh) | 2009-04-02 | 2014-07-09 | 默克专利有限公司 | 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物 |
| MX2011010218A (es) | 2009-04-02 | 2011-10-10 | Merck Patent Gmbh | Inhibidores de autotaxina. |
| EA020031B1 (ru) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| KR101184115B1 (ko) | 2009-08-31 | 2012-09-18 | 일동제약주식회사 | 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법 |
| US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| AU2011232058B2 (en) | 2010-03-26 | 2016-09-08 | Merck Patent Gmbh | Benzonaphthyridinamines as autotaxin inhibitors |
| JP2011219368A (ja) | 2010-04-02 | 2011-11-04 | Daiichi Sankyo Co Ltd | Ｎ−サリチルアミノ酸誘導体 |
| EP2606031B1 (en) | 2010-08-20 | 2017-09-27 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
| UY34094A (es) * | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| EP2714680B1 (en) | 2011-05-27 | 2015-11-25 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| WO2013061297A1 (en) | 2011-10-28 | 2013-05-02 | Pfizer Limited | Pyridazine Derivatives Useful in Therapy |
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| TW201500356A (zh) | 2013-04-12 | 2015-01-01 | Lilly Co Eli | 二氫吡啶并嘧啶化合物 |
| AP2016009020A0 (en) | 2013-07-18 | 2016-02-29 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
| US20160168119A1 (en) | 2013-07-18 | 2016-06-16 | Novartis Ag | Autotaxin inhibitors |
| US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
| CU24442B1 (es) | 2014-04-04 | 2019-09-04 | X Rx Inc | Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina |
| BR112016024473A2 (pt) | 2014-04-23 | 2018-01-23 | X Rx Inc | composto, composição farmacêutica, e, método para tratamento de uma doença e/ou condição |
-
2015
- 2015-04-03 CU CU2016000150A patent/CU24442B1/es unknown
- 2015-04-03 EA EA201691840A patent/EA201691840A1/ru unknown
- 2015-04-03 JP JP2017503794A patent/JP6616821B2/ja not_active Expired - Fee Related
- 2015-04-03 CA CA2943874A patent/CA2943874A1/en not_active Abandoned
- 2015-04-03 MD MDA20160116A patent/MD20160116A2/ro not_active Application Discontinuation
- 2015-04-03 WO PCT/US2015/024338 patent/WO2015154023A1/en not_active Ceased
- 2015-04-03 EP EP15773254.6A patent/EP3125895A4/en not_active Withdrawn
- 2015-04-03 SG SG11201607920RA patent/SG11201607920RA/en unknown
- 2015-04-03 US US15/300,762 patent/US10011601B2/en not_active Expired - Fee Related
- 2015-04-03 CN CN201580028170.3A patent/CN107106559A/zh active Pending
- 2015-04-03 PE PE2016001885A patent/PE20170206A1/es unknown
- 2015-04-03 CR CR20160496A patent/CR20160496A/es unknown
- 2015-04-03 AP AP2016009496A patent/AP2016009496A0/en unknown
- 2015-04-03 MX MX2016013049A patent/MX2016013049A/es unknown
- 2015-04-03 KR KR1020167030589A patent/KR20160133004A/ko not_active Withdrawn
- 2015-04-03 AU AU2015240519A patent/AU2015240519B2/en not_active Ceased
-
2016
- 2016-09-26 IL IL248050A patent/IL248050A0/en unknown
- 2016-09-28 PH PH12016501922A patent/PH12016501922A1/en unknown
- 2016-10-03 DO DO2016000270A patent/DOP2016000270A/es unknown
- 2016-10-04 CL CL2016002516A patent/CL2016002516A1/es unknown
- 2016-10-26 EC ECIEPI201684293A patent/ECSP16084293A/es unknown
-
2018
- 2018-02-14 US US15/896,905 patent/US10233182B2/en not_active Expired - Fee Related
-
2019
- 2019-04-12 US US16/256,429 patent/US20190225611A1/en not_active Abandoned
- 2019-11-08 JP JP2019203023A patent/JP2020040960A/ja active Pending
- 2019-11-15 AU AU2019264641A patent/AU2019264641A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513932A5 (enExample) | ||
| JP2017526614A5 (enExample) | ||
| JP2012532931A5 (enExample) | ||
| RU2016111659A (ru) | Соединение с агонистической активностью в отношении рецепторов соматостатина и его фармацевтическое применение | |
| JP2018519323A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| RU2010125220A (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| EP2582682B1 (en) | Mitotic kinesin inhibitors for use in the treatmetnof pulmonary arterial hypertension | |
| JP2016525075A5 (enExample) | ||
| JP2015504067A5 (enExample) | ||
| JP2013532713A5 (enExample) | ||
| CA2710122A1 (en) | Thiazole derivatives used as pi 3 kinase inhibitors | |
| JP2016514711A5 (enExample) | ||
| CN106573006A (zh) | 作为药物的rip1激酶抑制剂杂环酰胺 | |
| HRP20141190T1 (hr) | Disupstituirani derivati piridina kao antikancerogena sredstva | |
| ME02104B (me) | Inhibitori kinaza koji regulisu signalne puteve u apoptozi | |
| RU2015139590A (ru) | ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ | |
| RU2015120216A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2009536196A5 (enExample) | ||
| JP2016506964A5 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| JP2014518882A5 (enExample) | ||
| MX2010012290A (es) | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. | |
| JP2014037426A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2009515814A5 (enExample) |